Clinical Trials
11 trialsNCT03833180 2024-01-12
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Completed
NCT01991184 2022-06-21
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
Genentech, Inc.
Phase 1 Completed
NCT02556892 2019-08-14
A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT01680991 2016-04-25
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
Hoffmann-La Roche
Phase 1 Completed
NCT02556346 2016-03-02
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Molecular Templates, Inc.
Phase 1 Withdrawn
NCT00111683 2015-08-25
MK0457 in Patients With Leukemia (0457-003)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00464113 2015-08-21
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia
Exelixis
Phase 1 Terminated
NCT01292135 2014-07-24
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
Pharmacyclics LLC.
Phase 1 Completed
NCT00849654 2013-05-22
PCYC-04753
Pharmacyclics LLC.
Phase 1 Completed
NCT00108108 2012-10-01
Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy
Novartis
Phase 1 Terminated
NCT00452257 2009-03-19
A Study of Enzastaurin in Patients With Leukemia
Eli Lilly and Company
Phase 1 Completed